Details of the Drug

General Information of Drug (ID: DMAESQI)

Drug Name
MCY-M11
Indication
Disease Entry ICD 11 Status REF
Fallopian tube cancer 2C74 Phase 1 [1]
Ovarian cancer 2C73 Phase 1 [1]
Peritoneal cancer 2C51.Z Phase 1 [1]
Peritoneal mesothelioma 2C51.2 Phase 1 [1]
Drug Type
CAR-PBMC Cell therapy
Cross-matching ID
TTD ID
D8EIB7
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mesothelin (MSLN) TT4RXME MSLN_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Ovarian tissue
The Studied Disease Ovarian cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mesothelin (MSLN) DTT MSLN 1.35E-02 5.44 1.92
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03608618) Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of MaxCyte.